Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial

The ratio of ucGMP (urinary cyclic guanosine monophosphate) to BNP (B-type natriuretic peptide) is thought to reflect the responsiveness of tissues to natriuretic peptides. METHODS: We examined the relationship between ucGMP/BNP ratio and clinical outcomes, the effect of sacubitril/valsartan, compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Jawad H., Ibrahim, Wasyla, Dewan, Pooja, Desai, Akshay S., Køber, Lars, Prescott, Margaret F., Lefkowitz, Martin P., Rouleau, Jean L., Solomon, Scott D., Zile, Michael R., Packer, Milton, Jhund, Pardeep S., McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022671/
https://www.ncbi.nlm.nih.gov/pubmed/36943907
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.122.010111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022671/
https://www.ncbi.nlm.nih.gov/pubmed/36943907
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.122.010111

Ejemplares similares